Instead, it modulates several intersecting biological systems, which helps explain both its broad tissue effects and the complexity of establishing a clean dose-response relationship
recently employed complementary in vitro and in vivo methods to examine how altered MET signaling impacts synaptic development, observing an opposite effect on neuronal morphology in a stage-dependent way
If the TRIUMPH trials finish enrollment on schedule and read out in late 2025 or early 2026, Lilly could file an NDA in mid-to-late 2026
Recancostat is a patented combination of clinically studied ingredients including stabilized reduced glutathione (GSH), anthocyanins, and L-cysteine, to support cell apoptosis and healthy cell development.*
It is licensed for weight management in adults living with obesity (a BMI of 30 or above), or who are overweight (a BMI of 27 to under 30) with at least one weight related health condition, alongside a reduced calorie diet and increased physical activity
Ethics declarations Data availability The data behind the findings of this study are available from the corresponding author upon reasonable request
